Opinion|Videos|July 8, 2024
Treating Patients with SCLC with Driver Mutations
The Oncology Brothers and Eric Singhi, MD, provide clinical insights on the treatment of patients with small cell lung cancer with driver mutations.
Advertisement
Advertisement
Related to this article
The phase 3 DeLLphi-305 trial may support tarlatamab plus durvalumab as a new standard-of-care frontline maintenance option in extensive-stage SCLC.
Investigators will share detailed findings from the phase 1a/b EMBOLD PanTumour-101 study at the European Society for Medical Oncology Congress 2026.
Advertisement
Advertisement
Trending on CancerNetwork
1
Top Poster Takeaways for Prostate Cancer From 2026 ESMO Congress
2
INTerpath-001 Data Detail Survival, Subgroup, and Safety Findings in Melanoma
3
ctDNA Is Prognostic Regardless of Therapy in Cisplatin-Eligible MIBC
4
Tarlatamab Maintenance Combo Extends Survival in Extensive-Stage SCLC
5